Abstract
The ergot alkaloids were the first specific antimigraine therapy available. However, with the advent of the triptans, their use in the treatment of migraine has declined and their role has become less clear. This review discusses the pharmacology, efficacy, and safety of the ergots. In randomized clinical trials, oral ergotamine was found to be superior to placebo, but inferior to 100 mg of oral sumatriptan. In contrast, rectal ergotamine was found to have higher efficacy (73% headache relief) than rectal sumatriptan (63% headache relief). Intranasal dihydroergotamine was found to be superior to placebo, but less effective than subcutaneous and intranasal sumatriptan. Ergotamine is still widely used in some countries for the treatment of severe migraine attacks. It is generally regarded as a safe and useful drug if prescribed for infrequent use, in the correct dose, and in the absence of contraindications; however, safer and more effective options do exist in the triptans. In patients with status migrainous and patients with frequent headache recurrence, ergotamine is still probably useful.
Similar content being viewed by others
References and Recommended Reading
Tfelt-Hansen P, Saxena PR, Ferrari MD: Ergot alkaloids. In Handbook of Clinical Neurology, vol 21, Intoxications of the nervous system. Part II. Edited by Wolf FA. Amsterdam: Elsevier; 1995:61–78.
Tfelt-Hansen P, Saxena PR: Ergot alkaloids in the acute treatment of migraine. In The Headaches. Edited by Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia: Lippincott Williams & Wilkins; 2000:399–409. This reference presents an excellent and extensive review of the ergot alkaloids in the acute treatment of migraine.
Graham JR, Wolff HG: Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatr 1938, 39:737–763.
Buzzi MG, Moskowitz MA: Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. PMID 1991, 11:165–168.
Buzzi MG, Moskowitz MA, Peroutka SJ, Byun B: Further characterization of the putative 5HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br J Pharmacol 1991, 103:1421–1428.
Hoskin KL, Kaube H, Goadsby PG: Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiologic study. Brain 1996, 119:249–256.
Tfelt-Hansen P: Ergotamine, dihydroergotamine: current uses and problems. Curr Med Res Opin 2001, 17(suppl 1):30–34. A recent review with the personal point of view of the author regarding the current uses and problems of ergotamine and dihydroergotamine.
Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P: Arterial responses during migraine headaches. Lancet 1990, 336:837–839.
Stoll A: Zur Zenntinis der Mutterkornakkaloide. Verh Naturf Ges (Basel) 1920, 101:190–191.
Silberstein SD: The pharmacology of ergotamine and dihydroergotamine. Headache 1997, 37(suppl):15–25.
Stevens AA: Modern Materia Medica and Therapeutics. Philadelphia: WB Saunders; 1907.
MüIler-Schweinitzer E: Pharmacologic actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol 1984, 26:699–705.
Müller-Schweinitzer E. Weidmann H: Basic pharmacologic properties. In Ergot Alkaloids and Related Compounds. Edited by Berde B, Schild HO. Berlin: Springer-Verlag; 1978:87–232.
Welch KM, D’Andrea G, Tepley N, et al.: The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1990, 8:817–828.
Welch KM, Barkley GL, Tepley N, et al.: Central neurogenic mechanisms of migraine. Neurology 1993, 43:S21-S25.
Lauritzen M: Pathophysiology of the migraine aura: the spreading depression theory. Brain 1994, 117:199–210.
Lance JW, Lambert GA, Goadsby PJ, Duckworth JW: Brainstem influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraine. Headache 1983, 23:258–265.
Welch KM, Nagesh V, Aurora SK, Gelman N: Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001, 41:629–637.
Saito K, Markowitz S, Moskowitz MA: Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 1988, 24:732–737.
Goadsby PJ, Gundlach AL: Localization c: 3H-dihydroergotamine-binding sties in the cat central nervous system: relevance to migraine. Ann Neurol 1991, 29:91–94.
Tfelt-Hansen P, Eickhoff JH, Olesen J: The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve. Acta Pharmacol Toxicol 1980, 47:151–156.
Tfelt-Hansen P: Clinical pharmacology of ergotamine: an overview. In Drug-Induced Headache. Edited by Diener HC, Wilkinson M. Berlin: Springer-Verlags; 1988:105–116.
Perrin VL: Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet. 1985, 10:334–352.
Buzzi MG, Moskowitz MA, Peroutka SJ, Byun B: Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br J Pharmacol 1991, 103:1421–1428.
Little PJ, Jennings GL, Skews H, et al.: Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol 1982, 13:785–790.
Sandoz Pharmaceuticals Corporation: East Hanover, NJ. Data on file.
Ziegler D, Ford R, Kriegler J, et al.: Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994, 44:447–453.
Mathew NT: The abortive treatment of migraine. In Drug Therapy for Headache. Edited by Gallagher RM. New York: Marcel Dekker; 1991:95–114.
Saper JR, Silberstein SD, Gordon CD, Hamel RL: Medications used in the pharmacotherapy of headache. In Handbook of Headache Management: A Practical Guide to Diagnosis and Treatment of Head, Neck, and Facial Pain. Edited by Silberstein SD, Lipton RB. Baltimore: Williams & Wilkins; 1993:35–47.
Mathew NT: Dosing and administration of ergotamine tartrate and dihydroergotamine. Headache 1997, (suppl 1):26–32.
Baumel B: Migraine: a pharmacologic review with newer options and delivery modalities. Neurology 1994, 44(suppl 3):S13-S17.
Silberstein SD, Young WB: Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainous. Neurology 1995, 45:577–584.
Berde B, Stürmer E: Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In Ergot Alkaloids and Related Compounds. Edited by Berde B, Schild HO. Berlin: Springer-Verlag; 1978:1–28.
Chu D, Owen DAA, Stürmer E: Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad Med J 1976, 52(suppl 1):32–36.
Winner P, Dalessio D, Mathew N, et al.: Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache 1993, 33:471–475.
Winner P, Ricalde O, LeForce B, et al.: A double-blind study of subcutaneous dihydroergotamine versus subcutaneous sumatriptan in the treatment of acute migraine. Acta Neurol 1996, 53:180–184.
Belgrade MJ, Ling LJ, Schleevogt MB, et al.: Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache. Neurology 1989, 39:590–592.
Weisz MA, El-Raheb M, Blumenthal HJ: Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache 1994, 34:371–373.
Ziegler D, Ford R, Kriegler J, et al.: Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994, 44:447–453.
Mather PJ, Silberstein SD, Schulman EA, Hopkins MM: The treatment of cluster headache with repetitive IV dihydroergotamine. Headache 1991, 31:525–532.
Raskin NH: Modern pharmacotherapy of migraine. Neurol Clin 1990, 8:857–865.
Silberstein SD, Schulman EA, Hopkins MM: Repetitive IV DHE in the treatment of refractory headache. Headache 1990, 30:334–339.
Winner P, Dalessio D, Mathew N, et al.: Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. Am J Emerg Med 1994, 12:138–141.
Tfelt-Hansen P, Saxena PR, Dahlof C, et al.: Ergotamine in the acute treatment of migraine: European Consensus. Brain 2000, 123:9–18. Presents the European Consensus regarding the treatment of migraine with ergotamine.
Swedish Medical Products Agency: Monograph on sumatriptan suppositories. Accessible at http://mpa.se/lakemedel/ nn_lakeindex.html. Accessed July 5, 2001.
Callaham M, Raskin N: A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986, 26:168–171.
Scott AK: Dihydroergotamine: a review of its use in the treatment of migraine and other headaches. Clin Neuropharmacol 1992, 15:289–292.
Gallagher RM: Dihydroergotamine working group: acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol 1996, 53:1285–1291.
Queiroz LP, Weeks RE, Rapoport AM, et al.: Early and transient side effects of repetitive IV dihydroergotamine. Headache 1996, 36:291–294.
Galer BS, Lipton RB, Solomon S, et al.: Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache 1991, 31:446–450.
Scott AK: Dihydroergotamine: a review of its use in the treatment of migraine and other headaches. Clin Neuropharmacol 1992, 15:289–296.
Maassen Van Den Brink A, Reekers M, Bax WA, et al.: Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998, 7:25–30.
Lipton RB: Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 1997, 37(suppl 1):33–41.
Physicians’ Desk Reference, edn 49: Medical Economics Data. Montvale, NJ; 1995:1840,2149,2153.
Welch KMA: Relationship of stroke and migraine. Neurology 1994, 44(suppl 7):S33-S36.
Meyler WJ: Side effects of ergotamine. Cephalalgia 1996, 16:5–10.
Saper J: Ergotamine dependency: a review. Headache 1987, 27:435–438.
Silberstein SD, Saper JR, Freitag FG: Migraine, diagnosis, and treatment. In Wolff’s Headache and Other Head Pain. Edited by Silberstein SD, Lipton RB, Dalession DJ. New York: Oxford; 2001:121–237.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bigal, M.E., Tepper, S.J. Ergotamine and dihydroergotamine: A review. Current Science Inc 7, 55–62 (2003). https://doi.org/10.1007/s11916-003-0011-7
Issue Date:
DOI: https://doi.org/10.1007/s11916-003-0011-7